Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
ImmunityBio, Inc. (IBRX) had Stock-Based Compensation of $28.06M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$32.06M |
|
$-67.25M |
|
$0.18M |
|
$31.88M |
|
$87.69M |
|
$-55.63M |
|
$-11.68M |
|
$-67.31M |
|
$-67.31M |
|
$-67.27M |
|
$-67.27M |
|
$-67.27M |
|
$-67.27M |
|
$-55.63M |
|
$-51.68M |
|
946.60M |
|
946.60M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$329.50M |
|
$129.60M |
|
$189.49M |
|
$518.99M |
|
$57.13M |
|
$500.80M |
|
$985.26M |
|
$1.04B |
|
$-523.41M |
|
$-537.88M |
|
$-523.41M |
|
984.97M |
|
| Cash Flow Statement Financials | |
$-234.56M |
|
$-193.37M |
|
$345.35M |
|
$143.91M |
|
$61.34M |
|
$-82.58M |
|
|
Stock-Based Compensation |
$28.06M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.77 |
|
-- |
|
-- |
|
-22.15 |
|
-0.96 |
|
99.45% |
|
-173.51% |
|
-173.51% |
|
-- |
|
-209.94% |
|
-209.77% |
|
$-237.50M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
0.03 |
|
1.00 |
|
89.87 |
|
12.85% |
|
12.51% |
|
-12.96% |
|
297.59% |
|
$-0.53 |
|
$-0.25 |
|
$-0.25 |
|